Stemade Corporate Video - Dental Stem Cells
Know more about stem cells how preserving them can safe guard the future of our children.
By: StemadeBiotech
Read this article:
Stemade Corporate Video - Dental Stem Cells - Video
Dental Talk Show - Dental Stem Cells, Dental Show Preview Competition News
Host Nick Peters discusses Stem cell research and how the use of Stem Cells from Teeth are showing promising potential in the use of Stroke Therapy due to there likeness of Brain Neurons. #DentalNe...
By: NIck Peters
Read the original post:
Dental Talk Show - Dental Stem Cells, Dental Show Preview & Competition News - Video
Health Plus - Healing through Dental Stem Cells
Health Plus provides expert tips to prevent diseases that occur in the modern lifestyle. For Daily Updates and Fun Stuff Subscribe - http://www.youtube.com/u...
By: careworldtv
See the original post:
Health Plus - Healing through Dental Stem Cells - Video
Preserving dental stem cells Dr Bradley Briggs Scottsdale, Arizona
The notion of preserving your own stem cells has been gaining some popularity and researches have discovered a new way of preserving more off your cells and thats threw your teeth. Dr. Bradley Briggs from Briggs family cosmetic dentistry discusses the process and how we can preserve stem cells. Credits: http://www.youtube.com by LBNstudio.From:Kelly ChenViews:0 0ratingsTime:05:08More inScience Technology
Continue reading here:
Preserving dental stem cells Dr Bradley Briggs Scottsdale, Arizona - Video
The Wednesday Watch: Dental Stem Cell Banking Made Easier
Join us for this week #39;s Wednesday Watch and learn about some of the efforts being put forth for Oral Cancer Awareness Month. Also, hear about the new Executive Vice President at BISCO Dental Products, and gain some important insight on a new way to store dental stem cells. The winner of our March Sweepstakes for a one-ounce gold coin courtesy of Argen will be announced, so be sure to tune in!From:TheWednesdayWatchViews:140 0ratingsTime:04:34More inScience Technology
Read more here:
The Wednesday Watch: Dental Stem Cell Banking Made Easier - Video
Dr. David Stock - Anchor dental Group - Providing Store-A-Tooth trade; Dental Stem Cell Banking
Dr David Stock now provides the Store-A-Tooth trade; Service. Store-A-Tooth trade; is a service that enables families to store the dental stem cells from their own teeth. Eligible teeth include baby teeth that are naturally falling out, wisdom teeth, and other healthy teeth being extracted for orthodontia or other routine dental care.From:storeatoothViews:65 1ratingsTime:02:44More inScience Technology
More:
Dr. David Stock - Anchor dental Group - Providing Store-A-Tooth™ Dental Stem Cell Banking - Video
Georgia talks about storing her daughter #39;s dental stem cells and her hope for a cure to diabetes
Georgia talks about the day she found out her daughter had Type 1 Diabetes and the new "Store a Tooth. Find a Cure." campaign to help fund research for diabetes using dental stem cells. Type 1 diabetes may one day be cured by regenerating islet cells and blocking the immune system #39;s attack on the pancreas. Stem cells from teeth have been shown to be useful for both of these approaches, however little funding is focused on this type of research. Store-A-Tooth trade; is launching a campaign to fund diabetes research using dental stem cells. The campaign is called Store a Tooth. Find A Cure. Learn more: http://www.store-a-tooth.comFrom:storeatoothViews:141 2ratingsTime:01:45More inPeople Blogs
Excerpt from:
Georgia talks about storing her daughter's dental stem cells and her hope for a cure to diabetes - Video
Alexa talks about storing stem cells and her hope for a cure to diabetes
Alexa talks about banking dental stem cells and her hope for a cure to diabetes. Type 1 diabetes may one day be cured by regenerating islet cells and blocking the immune system #39;s attack on the pancreas. Stem cells from teeth have been shown to be useful for both of these approaches, however little funding is focused on this type of research. Store-A-Tooth trade; is launching a campaign to fund diabetes research using dental stem cells. The campaign is called Store a Tooth. Find A Cure. Learn more: http://www.store-a-tooth.comFrom:storeatoothViews:40 0ratingsTime:01:16More inScience Technology
Go here to read the rest:
Alexa talks about storing stem cells and her hope for a cure to diabetes - Video
Dental Stem Cells
From:greenhalghscottViews:60 2ratingsTime:03:45More inPeople Blogs
Here is the original post:
Dental Stem Cells - Video
Dr Jeremy Mao on Dental Stem Cells Type 1 Diabetes SD
I do not own this video but am just sharing this video. Dr. Jeremy Mao, Chief Science Advisor, StemSave discusses Dental Stem Cells, plasticity and potential treatment/cure for Type 1 Diabetes http://www.youtube.comFrom:Kelly ChenViews:5 0ratingsTime:05:11More inScience Technology
View post:
Dr Jeremy Mao on Dental Stem Cells Type 1 Diabetes SD - Video
The premier cosmetic dentist in Bergen County, Trinity Dental, is now offering patients $500 off dental implants. The discount reflects a significant reduction off of the regular price, and permits patients to receive an excellent implant placed by one of the accomplished implant dentists at the practice. Those interested should call (201) 351-0661.
Westwood, NJ (PRWEB) October 17, 2012
Trinity Dental is a dentist Westwood NJ trusts and provides treatment to all surrounding areas such as Elizabeth, Emerson, Oradell, Haworth, Harrington Park, Hillsdale, Washington Township, River Vale and Old Tappan.
Drs. Labib, Ibrahim and Pozzi at Trinity have over 40 collective years providing top notch dental implants, cosmetic dentistry, teeth whitening and laser dentistry to Bergen County. For the past 2 years, Dr. Labib was recognized as America's Top Dentist by the Consumer Research Council of America, in addition to being an instructor at Columbia University.
Trinity Dental offers comprehensive services with one of the newest being dental stem cell banking. This allows individuals to have their stem cells stored after removing wisdom teeth or after other extractions. Modern medicine continues to research uses of stem cell technology, so those cells may come in handy in the future.
The Bergen county dentists at Trinity are certified New Jersey Invisalign dentists, which are also called invisible braces. The clear aligners progressively straighten teeth while most people will not realize the person is wearing braces. Trinity Dental is offering an impressive $500 discount off Invisalign treatment.
Trinity Dental care uses state of the art treatments for consistently excellent patient care and offers stunning smile creation in a comfortable office.
To take advantage of the new patient specials for the $500 dental implants NJ discount or $500 off Invisalign, individuals should call (201) 351-0661.
Dr. Labib Trinity Dental Care (201) 351-0661 Email Information
More here:
Bergen County Dentist in Westwood NJ Now Offering $500 Off Dental Implants
Tuesday, Oct. 16, 2012
The government and universities began looking Monday into research projects involving Hisashi Moriguchi, who falsely claimed he had carried out the world's first clinical trial using a trailblazing stem cell technology.
The Cabinet Office and the science and health ministries, as well as the University of Tokyo, Tokyo Medical and Dental University and Kyorin University plan to probe what role Moriguchi may have played in the projects and whether his purported achievements are true.
Moriguchi, 48, said last week that he performed treatment using pluripotent stem (iPS) cells, which have the potential to grow into any type of body tissue, on six people but later admitted most of his claim was false.
"While the treatment was implemented, it was only one procedure," he said at a news conference Saturday in New York. "At the end of the day, I lied."
The education and science ministry found that Moriguchi was engaged in two research projects subsidized by the government between fiscal 2001 and 2005.
The projects, which received a combined 20.7 million in subsidies, concerned topics such as the comparison of cooperation between business and academia in Japan and the U.S. and did not involve experiments or surgery.
The Cabinet Office is set to provide 160 million in subsidies to a four-year project aimed at developing refrigeration techniques for cells and body organs that will run through fiscal 2013. The project leader at the University of Tokyo hired Moriguchi as a researcher.
The office has asked the Japan Society for the Promotion of Science, which manages the project, to look into Moriguchi's contributions.
A report submitted by the project members in fiscal 2010 said the research covers methods to refrigerate iPS cells, as well as organs such as the heart, uterus and lymph nodes, and that Moriguchi was a key researcher.
Read more:
All projects involving Moriguchi face probe
Miami, FL (PRWEB) October 15, 2012
Leveraging more than a decade of experience in the biotech industry and a founding member of GeneCell International, Jose Cirino, Director of Operations, is an industry expert for expanding awareness in the field of adult stem cells worldwide. Cirino plays a pivotal role in GeneCell Internationals success, managing all operational aspects of a company thats at the forefront of the biotech industry. While providing leadership and direction for the company, he is responsible for all strategic planning to help advance GeneCells mission and objectives, as well as the expansion of product, service and development at the national and international levels. Currently, Cirino is not only working on the expansion and awareness of cord blood services, but on the implementation of other adult stem cells sources, such as umbilical cord tissue, dental pulp, and adipose (fat) tissue into other countries. He has presentation talks in the advantage of adult cord blood banking to health and biotech industry organizations, conferences and small group meetings (both English and Spanish). Cirino was a key player in the expansion of GeneCell International into Miami, Florida, as the first and only stem cell laboratory of its kind in the South Floridian market and the gateway to international countries.
Through his field of work, Cirinos aspiration and passion is being able to assist individuals in potentially saving their life when a debilitating immune deficiency or disorder arises. Though, Cirino continuously asks himself, Why isn't everyone banking these cells?
His best assumption is that people are not informed about stem cell banking and what is most disheartening, some have never even heard of it. Most people are not aware they have stem cells in their body. Others believe that stem cells only come from only human embryos since this is whats mainly discussed in politics and the news today. May this be the reason they are choosing to have no part in it and ignore it? If so, this is not the case, these cells are found in adults and there are not controversial, moral, ethical or have any political issues surrounding them. The amazing thing about these cells, aside from their potential to treat a variety of different diseases, is that for the most part they can be harvested from the individual through relatively minimally invasive procedures and can be cryogenically frozen (at a temperature of -321 F (-196 C)) and stored for decades until a disease manifests itself or the needed for cell-based therapies arises," said Cirino.
Due to this lack of awareness, there is a massive shortage of stem cell units stored for future treatments. This shortage, or lack of availability, is mostly affecting patients of African, Asian, Hispanic and Native American Indian descent. I, being a minority member of this group, am very concerned by this shortage. Since patients who need a transplant are more likely to find a match within their own genetic background, Cirino adds it is important that the pool of donors reflects the overall community.
A persons blood stem cell type is inherited, which means a patient is more likely to find a matched donor from within their own ethnic group, more than half of cord blood donations and privately banked cord blood in the United States are from Caucasians while minorities remain underrepresented, significantly. By increasing awareness of the advantages of cord blood among minorities, there is a potential for increased access to therapies for more people.
Umbilical cord blood preservation is a process by which blood is collected from the umbilical cord of a newborn baby and is stored cryogenically in a specially-designated bank. According to the National Marrow Donor Program, cord blood contains cells that can be transfused to a patient to treat various diseases, including lymphoma and leukemia. Currently, there are approximately 80 treatable diseases and the list of illnesses continues to grow. Cord blood is rich in stem cells and because certain immune cells found in the cord blood are not mature, there is less risk for the recipients immune system to reject these cells. Cord blood can be used to treat the child from whom the blood was collected as well as some first-degree relatives who are a close genetic match, such as immediate family members. Additionally, patients can get the treatment in about three weeks - as opposed to six to eight for bone marrow from an adult donor.
Prior to founding GeneCell, Cirino served as the President of the International Division to a cord blood laboratory in Boston, Massachusetts, where he was responsible for identifying, evaluating and selecting international representatives for affiliate programs to expand the services internationally. In doing so, he coordinated laboratory development protocol license agreements and implemented these programs throughout various international countries. After the expansion into other countries, Cirino would manage the company owned offices as well as provide support to the affiliate offices, from Mexico and South America, to the UK and the Middle East. He also represented the company at international health and biotech industry conferences, implemented new sales tools and processes for all international divisions of the company, and oversaw all accounting tasks as a method of monitoring its sales projections. Cirino joined the company as the Accounting Manager, where he was responsible for all aspects of U.S. and international accounting functions. He is a seasoned accounting professional, holding various accounting positions within large companies such as Sir Speedy Printing Centers of Boston and Harvard Institute for International Development. He has served as a member within various industry organizations including the International Cord Blood Society, and New England Fertility Society, as well as participated in the International Federation of Gynecology and Obstetrics (FIGO), The Mexican Federation of Ultrasounds, The World Cord Blood Congress, and Stem Cells USA-Regenerative Medicine conferences.
In addition to cord blood, Cirinos implementation projects of other adult stem cells sources, in the U.S. and other countries, include Cord Tissue Segment, Dental Pulp and Adipose Tissue:
About Cord Tissue Segment - A gelatinous substance, which functions as the primary connective tissue of the umbilical cord and is referred to as Whartons Jelly. This segment contains an important amount of Mesenchymal stem cells. These cells are an excellent candidate for regenerative medicine and tissue engineering applications. Mesenchymal stem cells have shown great promise in the potential treatment of diseases such as heart attack, Parkinsons disease, Alzheimers disease, type I diabetes, assist in bone and dental regeneration and expedite wound healing. In the past, the umbilical cord has been viewed as medical waste and discarded, resulting in the loss of this potential life-saving resource. By storing the stem cells extracted from your umbilical cord tissue segment along with your babys cord blood, youll have access to a wider variety of stem cells as new scientific discoveries are made.
Continued here:
Director of Operations for GeneCell International, Jose Cirino, Accentuates the Importance Surrounding the Minority ...
Friday, Oct. 12, 2012
Harvard University said neither it nor Massachusetts General Hospital have ever authorized any iPS-related clinical studies by Hisashi Moriguchi, who claims to have achieved the first clinical application using the revolutionary stem cell technology.
"No clinical trials related to Moriguchi's work have been approved by institutional review boards at either Harvard University or Massachusetts General Hospital," a statement issued by Harvard and related institutes said Thursday.
The statement confirmed that Moriguchi "was a visiting fellow at Massachusetts General Hospital from 1999-2000," but added that he "has not been associated with (the institution) or Harvard since that time."
Moriguchi, a researcher at University of Tokyo Hospital, claimed to be a visiting lecturer at Harvard and to have conducted clinical trials at Massachusetts General Hospital with other researchers to transplant artificial cardiac muscle cells developed from iPS cells into six patients with heart disease.
The claim came just after Shinya Yamanaka of Kyoto University and a British scholar were jointly awarded this year's Nobel Prize in physiology or medicine for their research on iPS cells. Yamanaka and John Gurdon were credited with the discovery that mature human cells can be reprogrammed as immature cells capable of developing into all types of body parts.
"Research has been conducted after going through due procedures, such as consultations with a university ethics committee," Moriguchi claimed. "I have been told my method of creating iPS cells is different from the one used by Yamanaka (and Gurdon), but I have been doing it my way and no problems have been identified after transplants."
Moriguchi, who is thought to have asked a heart surgeon to carry out cell transplants, unveiled details about the treatment at a meeting of annual stem-cell research conference at Rockefeller University in New York held Wednesday and Thursday.
But the event's organizer, the nonprofit New York Stem Cell Foundation, subsequently said it "has received information from Harvard University that raises legitimate questions concerning a poster presentation" by Moriguchi, and has withdrawn it from the conference.
Moriguchi graduated from Tokyo Medical and Dental University with a degree in nursing science and does not have a license to practice medicine, according to a professor who taught him as an undergraduate.
Read more:
Doubt cast on clinical stem cell tests
NEW YORK, Oct. 8, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), an emerging leader in the fast growing cell therapy market, announced today that data from its collaborative studies with the University of Michigan School of Dentistry further expands the therapeutic potential of its proprietary regenerative cell therapy product, "VSELSTM" (very small embryonic-like stem cells), by demonstrating bone regeneration capabilities in a study published online ahead of print1 in the journal Stem Cells and Development (DOI: 10.1089/scd.2012.0327). The paper highlights that human VSEL stem cells form human bone when implanted in the bone tissue of SCID mice.
VSELs are a population of stem cells found in adult bone marrow with potential regenerative properties similar to those of embryonic stem cells. NeoStem has shown that these cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what NeoStem believes to be a population of stem cells that have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or the potential negative effects known to be associated with embryonic stem cells.
This published controlled study, funded by NIH and led by Dr. Russell Taichman, Major Ash Collegiate Professor and Co-Director of the Scholars Program in Dental Leadership Department of Periodontics & Oral Medicine, University of Michigan and Dr. Aaron Havens, Department of Orthodontics and Pediatric Dentistry at University of Michigan, involved isolating G-CSF mobilized VSEL stem cells from the blood of healthy donors and transplanting them into burr holes made in the cranial bones of SCID mice. After three months, it was observed that the implanted VSEL stem cells had differentiated into human bone tissue in the crania of the mice. Dr. Taichman stated, "I believe this work represents a true partnership between Industry and Academic Institutions. Our findings that VSEL cells can generate human bone in animals would not have been feasible without the help and vision that Dr. Denis Rodgerson and his team at NeoStem brought to the table. It was my privilege to have been a part of this collaborative effort, and I see the resulting data as a significant milestone in stem cell therapy development. It is truly inspiring."
Dr. Robin Smith, Chairman and CEO of NeoStem, added, "This is very exciting data that we believe will be the foundation for future VSEL stem cell studies of bone regeneration in humans. We look forward to moving the development work from the laboratory into the clinic to develop a therapeutic stem cell product to enhance bone formation in humans."
About NeoStem, Inc.
NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.
Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.
Forward-Looking Statements for NeoStem, Inc.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to (i) the Company's ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company's clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company's ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property, (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
(1) Human Very Small Embryonic-Like Cells Generate Skeletal Structures, In Vivo. Havens A., et al., Stem Cells and Development.
See the original post here:
NeoStem Announces Very Small Embryonic-Like Cells (VSEL(TM)) Publication in Stem Cells and Development
PARAMUS, N.J., Oct. 4, 2012 /PRNewswire/ --PROTEONOMIX, INC. (PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Company's clinical trial of UMK-121 has received IRB (Institutional Review Board) approval and is now ready for the recruitment of patients.
We thank the University of Medicine & Dentistry of New Jersey for providing the IRB and their invaluable contribution to this study of the UMK-121 drug therapy on patients with End Stage Liver Disease.
To better understand what a clinical trial is please visit the following links: Overview; Rising Cost of Clinical Trial; Additional information on Clinical Trials .
As previously announced, the Company entered into an Agreement to conduct the clinical trial with the UMDNJ. That Agreement required the Company to pay expenses associated with the clinical study which the Company has done to date.
Michael Cohen, President of the Company, stated: "The financing that was required to complete the Company's obligation with respect to the Trial was provided by the private placement of our Series E Preferred Stock on Friday, March 9, 2012. We previously announced that we have engaged the University to conduct the trial and thanked the University for their assistance with the finalization of the agreement to conduct a clinical trial of UMK-121. The Company has previously described the terms of the agreement to license and develop and the patent application of the UMK-121 technology. The Company will work together with the University and the principal investigators to initiate the clinical study. The approval of the IRB was required before the study could go forward. The investigators can now accept patients into the study."
About the University of Medicine and Dentistry of New Jersey
The University of Medicine and Dentistry of New Jersey (UMDNJ) is New Jersey's only health sciences university with more than 6,000 students on five campuses attending three medical schools, the State's only dental school, a graduate school of biomedical sciences, a school of health related professions, a school of nursing and New Jersey's only school of public health. UMDNJ operates University Hospital, a Level I Trauma Center in Newark, and University Behavioral HealthCare, which provides a continuum of healthcare services with multiple locations throughout the State.
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at http://www.proteonomix.com and http://www.proteoderm.com.
Forward-looking statements:
View original post here:
Proteonomix, Inc. Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease
Directors of GeneCell International, a cutting-edge facility specialized in the processing and cryogenic preservation of umbilical cord blood, cord tissue, dental pulp and adipose stem cells, attends the Stem Cells USA & World Cord Blood Congress 2012.
Miami, FL (PRWEB) October 01, 2012
The event was attended by 300+ notable and prominent doctors, scientists and regulators in the field of stem and featured numerous keynote speakers. The program kicked-off with the chairmans opening remarks on the perspective on the cord blood market. Entities involved in the collection, processing, cryopreservation, transplantation and research shared their and experiences with the rapidly evolving future of cord blood stem cells and related tissues. Some presentation topics included were:
Umbilical cord blood preservation is a process by which blood is collected from the umbilical cord of a newborn baby and is stored cryogenically in a specially-designated bank. According to the National Marrow Donor Program, cord blood contains cells that can be transfused to a patient to treat various diseases, including lymphoma and leukemia. Currently, there are approximately 80 treatable diseases and the list of illnesses continue to grow. Cord blood is rich in stem cells and there is less risk for the recipients immune system to reject the cells, because certain immune cells found in the cord blood are not mature. Cord blood can be used to treat the child from whom the blood was collected as well as some first-degree relatives who are a close genetic match, such as family members. Additionally, patients can get the treatment in about three weeks - as opposed to six to eight for bone marrow from an adult donor.
A persons blood stem cell type is inherited, which means a patient is more likely to find a matched donor from within their own ethnic group, said GeneCells Director of Operations, Jose Cirino. More than half of cord blood donations and privately banked cord blood in the United States are from Caucasians while minorities remain underrepresented. By increasing the awareness of cord blood advantages among minorities, there is a potential for increased access to therapies for more people.
The shortage, or lack of availability, affects patients of African, Asian, Hispanic and Native American Indian descent. Since patients who need a transplant are more likely to find a match within their own race, Cirino adds it is important that the pool of donors reflects the overall community.
Why isn't everyone banking these cells? What transpires is that people are not informed about stem cell banking and some have never even heard of it. Most people are not aware they have stem cells in their body, they believe that stem cells only come from human embryos since that is what is mainly discussed in politics and the news. However, this is not the case. These cells are found in adults and there are no moral, ethical or political issues surrounding these cells.
The amazing thing about these cells, aside from their potential to treat a variety of different diseases, is that for the most part they can be harvested from the individual through relatively minimally invasive procedures and can be cryogenically frozen (at a temperature of -321 F) and stored for decades until a disease manifests or they are needed for cell-based therapies added GeneCells Director of Research & Laboratory Operations, Dr. Todd R. Flower.
GeneCell International specializes in the collection, transport, processing and cryogenic storage of adult stem cells from various sources including; umbilical cord blood, cord tissue, dental pulp and adipose tissue (fat) that can later be used to treat a variety of diseases. The laboratory is also involved in scientific research and development with a range of stem cells from various adult tissues. The facility is governed and inspected by the FDA as well several other regulating bodies to ensure the safety of these cellular therapies.
Alongside its commitment to educating the public on the benefits of cord blood preservation, GeneCell is committed to being on the forefront of stem cell research. GeneCell International is the only Cord Blood, Cord Tissue and Dental Pulp Processing and Cryogenic Storage Laboratory to offer this cutting-edge, regenerative medicine technology in Miami, Florida.
Read the original here:
GeneCell International, Miami’s Only and Preferred Cord Blood Laboratory, Participates in The Stem Cells USA & World ...
It is a dream for everyone as they grow older to turn back the clock and live in a younger body once again. While many have developed ways to make the body look younger cosmetically, there have been very few effective methods to combat the aging process within the body until now.
For the first time ever, researchers have identified a crucial protein responsible for the decline of muscle repair and agility as the body ages. Upon this discovery, the scientists were able to effectively halt muscle decline in mice, giving hope to similar treatments for humans in the future.
According to the studys authors, loss of muscle strength and repair is one of the major concerns facing elderly citizens.
A great advantage of medicine is that people are not dying as early as they used to, but the body hasnt figured out how to maintain its muscle repair, Andrew Brack, of the Massachusetts General Hospital Center for Regenerative Medicine and corresponding study author, told FoxNews.com. The average loss of muscle mass for the 80-year-old male is 40 percent. Elderly people will fall over and break bones, they go to the hospital where they lose more muscle strength, and then dont recover.
Brack noted that muscle strength is also one of the main factors that keeps elderly individuals out of the hospital and allows them to be productive members of the workforce. In order to combat this muscle decline, Brack and Albert Basson, who met at Kings College London, teamed up to see if they could put the process in reverse.
The key revolves around stem cells found within muscles. During exercise or injury, these stem cells become activated and work fervently by dividing and multiplying into new muscle fibers that help to repair the muscle. When they are no longer need, they retreat into a reservoir within the muscle and lay dormant until they are needed again.
The problem with aging muscles is that these fixer stem cells dont remain dormant when theyre not needed. Instead, they become activated more and more and unnecessarily divide and multiply causing them to die at a faster rate. Since muscles only have a finite amount of these stem cells, the quicker the cells die, the less effective muscles become at repairing themselves.
Wondering exactly why the stem cells became more activated with age, Brack and Basson screened older muscles, finding higher levels of a protein called FGF2 a protein that stimulates cell division. The scientists figured these levels could explain the unnecessary cell activation.
As your muscle gets old, you start making more of this FGF2 protein, Basson, senior lecturer at Kings College London Dental Institute, told FoxNews.com. When theres more, the FGF2 starts waking up these stem cells and they start dividing. The stem cells have a limited number of times they can divide before they die or differentiate into other cells.
Basson figured that if they were able to boost a gene called SPRY2, which inhibits FGF2, then the stem cells would lay dormant until they were absolutely needed. To test this theory, the researchers administered a common drug containing SPRY2 to suppress FGF2 levels in elderly mice. Sure enough, the drugs halted the decline of muscle stem cells in the mice.
Follow this link:
Reverse aging? Scientists find way to make old muscles young again
Editor's Choice Main Category: Stem Cell Research Also Included In: Seniors / Aging Article Date: 27 Sep 2012 - 12:00 PDT
Current ratings for: Scientists Discover How To Halt Aging Muscles
4.27 (11 votes)
This groundbreaking study, published in Nature, explains why muscle mass decreases with age, an important factor in weakness, causing lack of mobility and falls in elders.
Previous research has told us that stem cells can play a crucial role in stimulating muscle regeneration. This particular study looked at stem cells found in muscles that are responsible for repairing injuries and why the muscles' capacity of regeneration deteriorates with age.
An inactive supply of stem cells is present inside every muscle, ready to be put into action by exercise or injury to fix any damage. When these stem cells are needed, they can divide into hundreds of new muscle threads and repair the injured muscle. At the end of the repairing process, a few of these cells refill the supply of dormant stem cells, enabling the muscle to carry on repairing itself continuously.
Researchers used elderly mice to conduct this study and found the number of inactive stem cells in the extra pool decreases with age, explaining the decline in the muscle's ability to regenerate and repair as the body gets older. When these muscles were examined, the scientists found high levels of FGF2, a protein that has the capacity to trigger the division of cells. While stimulating inactive cells to split and repair muscle is a normal and vital process, they found FGF2 could awaken the dormant stem cells even when they were not needed. Continuous activation of the dormant stem cells meant depletion of the surplus, leaving the muscles without necessary stem cells when repair was really needed.
After this finding, the team attempted to obstruct FGF2 in old muscles in order to prevent the stem cell surplus from being activated unnecessarily. By giving the mice a common FGF2 inhibitor drug, they were able to slow down the decline in the number of muscle stem cells.
Dr Albert Basson, Senior Lecturer from the Department of Craniofacial Development and Stem Cell Biology at the King's College London Dental Institute, said:
Written by Kelly Fitzgerald Copyright: Medical News Today Not to be reproduced without permission of Medical News Today
SAN FRANCISCO, Sept. 18, 2012 /PRNewswire/ -- Case results published in the journal Cell Transplantation revealed that human craniofacial tissues regenerate faster using stem cells than with traditional bone regeneration therapy.
San Francisco dentist Dr. Greg Larson awaits the benefits this research has in store for restorative dentistry treatments.
The University of Michigan School of Dentistry, the Michigan Center for Oral Health Research and Aastrom Biosciences, Inc. in Ann Arbor, Mich., performed research in a dual effort. Clinical trials included 24 participants needing jawbone reconstruction following tooth extraction. Researchers prescribed some participants bone regeneration therapy, while others received ixmyelocel-T cells, developed by Aastrom Biosciences.
Aastrom researchers used the bone marrow of participants to create a variety of cell types, including stem cells that would later be implanted into their mouths and jaws.
"Patients who received tissue repair cells achieved greater bone density and quicker bone renewal and required less bone grafting during implant procedures when compared to those who underwent traditional guided bone regeneration therapy," according to the U-M press release.
U-M School of Dentistry Assistant Professor Darnell Kaigler says the regenerated bone will provide dentists with a stronger foundation when using dental implants. By replacing missing teeth with dental implants, dentists like Larson can improve a patient's ability to eat, speak and smile normally.
Kaigler, also the principal investigator on the project, added that another benefit of this treatment method is that patients can renew tissues using their own cells, as opposed to exposing their bodies to foreign cells.
See the rest here:
San Francisco Dentist Follows Stem Cell Research Regarding Craniofacial Tissue Renewal